Genetic testing can be a fearful, daunting, overwhelming, exciting, or joyful experience. In many cases, the emotions of people who pursue genetic testing can be described with more than just one of ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, ...

A large-scale genomic study of koalas across eastern Australia has found that populations that went through severe 20th-century bottlenecks are already showing signs of genetic recovery, challenging ...

Myriad Genetics beat estimated earnings by 180.0%, reporting an EPS of $0.04 versus an estimate of $-0.05. Revenue was down $800 thousand from the same period last year. In the previous quarter, the ...